Biosino Bio-Technology and Science Incorporation (8247.HK)
- Previous Close
0.620 - Open
0.620 - Bid 0.480 x --
- Ask 0.610 x --
- Day's Range
0.620 - 0.620 - 52 Week Range
0.260 - 1.380 - Volume
6,000 - Avg. Volume
6,135 - Market Cap (intraday)
88.271M - Beta (5Y Monthly) -0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-0.320 - Earnings Date Mar 25, 2025 - Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 28, 2019
- 1y Target Est
--
Biosino Bio-Technology and Science Incorporation, together with its subsidiaries, manufactures, sells, and distributes in-vitro diagnostic reagents in Mainland China. It offers clinical chemistry reagents, including single and double reagents, calibrators, QC products, and washing solution detergents; Elisa kits; rapid tests; and analyzers. The company also provides medical and medical inspection services; produces and sells medical instruments; and researches and develops, sells, and distributes biological reagents and instruments. The company was founded in 1988 and is based in Beijing, the People's Republic of China.
www.sinobio.com.cn499
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 8247.HK
View MorePerformance Overview: 8247.HK
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 8247.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 8247.HK
View MoreValuation Measures
Market Cap
89.72M
Enterprise Value
181.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.32
Price/Book (mrq)
0.50
Enterprise Value/Revenue
0.64
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-16.17%
Return on Assets (ttm)
-4.95%
Return on Equity (ttm)
-28.03%
Revenue (ttm)
263.07M
Net Income Avi to Common (ttm)
-42.53M
Diluted EPS (ttm)
-0.320
Balance Sheet and Cash Flow
Total Cash (mrq)
68.21M
Total Debt/Equity (mrq)
88.18%
Levered Free Cash Flow (ttm)
--